View |
|
BR-1394
|
Trastuzumab
|
Trazimera
|
150 mg
|
Powder For Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
15 mL Type I clear glass vial with chlorobutyl
stopper and aluminum crimp seal with flip-off cap (Box of 1's)
|
Monoclonal Antibodies [HER2 (Human Edpidermal Growth Factor Receptor 2) Inhibitors)
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
N/A
|
Pfizer, Inc.
|
Pfizer, Inc.
|
Initial
|
30 March 2022
|
30 March 2027
|
View |
|
BR-1395
|
Trastuzumab
|
Trazimera
|
440 mg
|
Powder For Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
30 mL Type I clear glass vial with chlorobutyl rubber
stopper and aluminum crimp with flip-off cap + 20 mL Type I clear glass vial with bromobutyl rubber stopper and aluminum crimp with flip-off cap (Bacteriostatic Water for Injection as diluent) (Box of 1's)
|
Monoclonal Antibodies [HER2 (Human Edpidermal Growth Factor Receptor 2) Inhibitors)
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
N/A
|
Pfizer, Inc.
|
Pfizer, Inc.
|
Initial
|
30 March 2022
|
30 March 2027
|
View |
|
BR-1396
|
Polatuzumab vedotin
|
Polivy
|
140 mg
|
Powder for Concentrate for Solution for
Infusion (IV)
|
Prescription Drug (Rx)
|
Single dose. 20 mL USP/Ph. Eur./JP Type I borosilicate glass vial with rubber stopper, aluminum seal and blue plastic flip-off cap (Box of l's)
|
-
|
BSP Pharmaceuticals S.p.A.
|
Italy
|
|
Roche (Philippines), Inc.
|
Roche (Philippines), Inc.
|
Monitored Release
|
01 April 2022
|
01 April 2027
|
View |
BR-1397_PI_01.pdf
|
BR-1397
|
Brolucizumab
|
Vsiqq
|
120 mg/mL (27.6 mg/0.23 mL)
|
Solution for Injection (Intravitreal)
|
Prescription Drug (RX)
|
Single use. 0.23 mL in 2 mL Ph. Eur. Type I
colourless glass vial with grey rubber stopper and an aluminum seal with violet flip-off cap + 1 12" 18G filter needle in a soft blister (Box of l's)
|
Antineovascularization Agent
|
Novartis Pharma Stein AG Technical Operations
|
Switzerland
|
|
Novartis Healthcare Philippines, Inc.
|
|
Monitored Release (MR)
|
01 April 2022
|
01 April 2027
|
View |
BR-1398_PI_01.pdf
|
BR-1398
|
Secukinumab
|
Cosentyx
|
300 mg/ 2 mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
2.25 mL (Net content: 2 mL) Type I pre-filled glass syringe with grey bromobutyl rubber plunger stopper, stainless steel 276 2" needle and rubber needle shield, assembled in an autoinjector pen (Box of l's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
Operations Schweiz Steriles
|
Switzerland
|
N/A
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Initial
|
13 April 2022
|
13 April 2027
|
View |
|
BR-1399
|
Secukinumab
|
Cosentyx
|
300 mg/ 2 mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
2.25 mL (Net content: 2 mL) Type I pre-filled glass syringe with grey bromobutyl rubber plunger stopper, stainless steel 276 12" needle and rubber needle shield, assembled in an Ultra Safe PassiveTM X225L needle safety device (Box of 1's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
Operations Schweiz Steriles
|
Switzerland
|
N/A
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Initial
|
13 April 2022
|
13 April 2027
|
View |
|
BR-1400
|
Trastuzumab
|
Trazimera
|
440 mg
|
Powder for Concentrate for Solution for Infusion (IV)
|
Prescription Drug (RX)
|
30 mL Type I clear glass vial with chlorobutyl
stopper sealed with aluminum and flip-off cap (drug product) + 20 mL Type I clear glass vial with bromobutyl rubber stopper sealed with aluminum and flip-off cap (Bacteriostatic Water for Injection as diluent) [Box of 1's]
|
Monoclonal Antibodies
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
N/A
|
Pfizer, Inc.
|
Pfizer, Inc.
|
Initial
|
21 April 2022
|
21 April 2027
|
View |
|
BR-1401
|
Trastuzumab
|
Kanjinti
|
150 mg
|
Powder For Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
20 mL Type I borosilicate glass vial with a butyl rubber stopper and an aluminum seal with flip-off dust cover (box of 1's)
|
-
|
Amgen Technology (Ireland) Unlimited Company
|
Ireland
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Initial
|
20 May 2022
|
20 May 2027
|
View |
BR-1402_PI_01.pdf
|
BR-1402
|
Bevacizumab
|
Abevmy
|
400 mg / 16 mL (25 mg/mL)
|
Vascular Endothelial Growth Factor Inhibitors
|
Prescription Drug (RX)
|
USP Type I clear glass vial with grey chlorobutyl rubber stopper and aluminum seal with plastic flip-off cap x 16 mL (Box of 1's)
|
Vascular Endothelial Growth Factor Inhibitors
|
Biocon Limited
|
India
|
N/A
|
Viatris Pharmaceuticals, Inc.
|
Viatris Pharmaceuticals, Inc.
|
Initial (Reconstruction)
|
15 March 2023
|
23 May 2027
|
View |
BR-1403_PI_01.pdf
|
BR-1403
|
Bevacizumab
|
Abevmy
|
100 mg / 4mL (25 mg/mL)
|
Concentrate For Solution Fo Infusion (IV)
|
Prescription Drug (RX)
|
USP Type I clear glass vial with grey chlorobutyl rubber
stopper and aluminum seal with plastic flip-off cap x 4 mL (Box of 1's)
|
Vascular Endothelial Growth Factor Inhibitors
|
Biocon Limited
|
India
|
N/A
|
Viatris Pharmaceuticals, Inc.
|
Viatris Pharmaceuticals, Inc.
|
Initial (Reconstruction)
|
14 March 2023
|
23 May 2027
|
View |
|
BR-1404
|
Rituximab
|
Ruxience
|
10mg/mL
|
Concentrate for Solution for Infusion (IV)
|
Prescription Drug (RX)
|
Single dose. Type I clear glass vial with chlorobutyl rubber stopper and aluminum crimp seal with flip-off cap (Box of l’s) [Net content: 10 mL and 50 mL]
|
Monoclonal Antibodies
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
N/A
|
Pfizer, Inc.
|
Pfizer, Inc.
|
Initial
|
30 May 2022
|
30 May 2027
|
View |
|
BR-1405
|
Rituximab
|
Redditux
|
10mg/mL
|
Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
USP Type I Borosilicate glass vial with grey butyl rubber stopper, sealed with aluminum crimp and polypropylene flip-off cap x10 mL and 50 mL
|
-
|
Dr. Reddy's Laboratories Ltd.
|
India
|
N/A
|
Dr. Reddy's Laboratories Philippines Inc.
|
Dr. Reddy's Laboratories Philippines Inc.
|
Initial
|
21 June 2022
|
21 June 2027
|
View |
|
BR-1406
|
Insulin Aspart
|
Fiasp
|
100 Units (equivalent to 3.5 mg)/mL
|
Solution for
Injection (IV/SC)
|
Prescription Drug (RX)
|
10 mL Type I glass vial with bromobutyl rubber stopper and aluminum flip-off cap (Box of 1's)
|
Antidiabetics
|
Novo Nordisk Pharmaceutical Industries, LP
|
United States of America
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Initial
|
14 July 2022
|
14 July 2027
|
View |
|
BR-1407
|
Pertuzumab + Trastuzumab
|
Phesgo
|
1200 mg / 600 mg/ 15 mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
15 mL in 20mL type I glass vial with butyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1's)
|
-
|
F. Hoffmann-La Roche, Ltd.
|
Switzerland
|
F. Hoffmann-La Roche Ltd.
|
Roche (Philippines) Inc.
|
Roche (Philippines) Inc.
|
Monitored Release
|
29 July 2022
|
29 July 2027
|
View |
|
BR-1408
|
Pertuzumab + Trastuzumab
|
Phesgo
|
600 mg / 600 mg/ 10mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
10 mL in 15mL type I glass vial with butyl rubber stopper and aluminum seal with plastic flip-off cap (Box of 1's)
|
-
|
F. Hoffmann-La Roche, Ltd.
|
Switzerland
|
F. Hoffmann-La Roche Ltd.
|
Roche (Philippines) Inc.
|
Roche (Philippines) Inc.
|
Monitored Release
|
29 July 2022
|
29 July 2027
|
View |
|
BR-1409
|
Epoetin Alfa
|
Erysaa
|
4,000 IU/0.4 mL
|
Solution for Injection (IV)
|
Prescription Drug (RX)
|
1 mL (Net content: 0.4 mL) Type I pre-filled glass syringe with bromobutyl plunger stopper, 276 12" needle and rubber needle shield (Box of 6's)
|
-
|
PanGen Biotech Inc.
|
Korea
|
N/A
|
DB (Philippines), Inc.
|
DB (Philippines), Inc.
|
Initial
|
16 August 2022
|
16 August 2027
|
View |
|
BR-1410
|
Sulodexide
|
Angioflux
|
250 LSU
|
Softgel Capsule
|
Prescription Drug (RX)
|
In a box of 2 Clear PVC/Alu Blister Pack x 25's
|
-
|
Catalent Italy S.P.A.
|
Italy
|
Aesculapius Farmaceutici S.r.l.
|
Lakeside Pharmaceuticals Phil., Inc.
|
Lakeside Pharmaceuticals Phil., Inc.
|
Automatic Renewal (Reconstruction)
|
23 August 2022
|
28 December 2025
|
View |
BR-1411_PI_01.pdf
|
BR-1411
|
Semaglutide
|
Rybelsus
|
7 mg
|
Tablet
|
Prescription Drug (RX)
|
Alu/Alu blister pack x 10's (box of 30's, 60's, and 90's)
|
Glucagon-like Peptide-1 (GLP-1) Analogue
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release
|
18 August 2022
|
18 August 2027
|
View |
BR-1412_PI_01.pdf
|
BR-1412
|
Semaglutide
|
Rybelsus
|
14 mg
|
Tablet
|
Prescription Drug (RX)
|
Alu/Alu blister pack x 10's (box of 30's, 60's, and 90's)
|
Glucagon-like Peptide-1 (GLP-1) Analogue
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release
|
18 August 2022
|
18 August 2027
|
View |
BR-1413_PI_01.pdf
|
BR-1413
|
Semaglutide
|
Rybelsus
|
3 mg
|
Tablet
|
Prescription Drug (RX)
|
Alu/Alu blister pack x 10's (box of 30's, 60's, and 90's)
|
Glucagon-like Peptide-1 (GLP-1) Analogue
|
Novo Nordisk A/S
|
Denmark
|
N/A
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Novo Nordisk Pharmaceuticals (Philippines), Inc.
|
Monitored Release
|
18 August 2022
|
18 August 2027
|